126 related articles for article (PubMed ID: 37358989)
1. Focal therapy of prostate cancer: Assessment with prostate-specific membrane antigen (PSMA) imaging.
Topoozian M; Calais J; Felker E; Sisk A; Gonzalez S; Lee SJ; Marks LS
Urol Case Rep; 2023 Sep; 50():102461. PubMed ID: 37358989
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3.
Liu C; Liu T; Zhang Z; Zhang N; Du P; Yang Y; Liu Y; Yu W; Li N; Gorin MA; Rowe SP; Zhu H; Yan K; Yang Z
J Nucl Med; 2020 Sep; 61(9):1314-1319. PubMed ID: 32034111
[TBL] [Abstract][Full Text] [Related]
4. Determining the diagnostic value of PSMA-PET/CT imaging in patients with persistent high prostate specific antigen levels and negative prostate biopsies.
Bodar Y; Koene B; Meijer D; van Leeuwen PJ; Nadorp S; Donswijk ML; Hendrikse NH; Oprea-Lager DE; Vis AN
Urol Oncol; 2022 Feb; 40(2):58.e1-58.e7. PubMed ID: 34404590
[TBL] [Abstract][Full Text] [Related]
5. Safety and Diagnostic Yield of
Kumar R; Singh SK; Mittal BR; Vadi SK; Kakkar N; Singh H; Krishnaraju VS; Kumar S; Bhattacharya A
Radiology; 2022 May; 303(2):392-398. PubMed ID: 35191735
[TBL] [Abstract][Full Text] [Related]
6.
Zhang LL; Li WC; Xu Z; Jiang N; Zang SM; Xu LW; Huang WB; Wang F; Sun HB
Eur J Nucl Med Mol Imaging; 2021 Feb; 48(2):483-492. PubMed ID: 32734457
[TBL] [Abstract][Full Text] [Related]
7. Prospective Evaluation of
Lopci E; Lughezzani G; Castello A; Saita A; Colombo P; Hurle R; Peschechera R; Benetti A; Zandegiacomo S; Pasini L; Casale P; Pietro D; Bevilacqua G; Balzarini L; Buffi NM; Guazzoni G; Lazzeri M
Eur Urol Focus; 2021 Jul; 7(4):764-771. PubMed ID: 32312701
[TBL] [Abstract][Full Text] [Related]
8. The PRIMARY Score: Using Intraprostatic
Emmett L; Papa N; Buteau J; Ho B; Liu V; Roberts M; Thompson J; Moon D; Sheehan-Dare G; Alghazo O; Agrawal S; Murphy D; Stricker P; Hope TA; Hofman MS
J Nucl Med; 2022 Nov; 63(11):1644-1650. PubMed ID: 35301240
[TBL] [Abstract][Full Text] [Related]
9.
Burger IA; Müller J; Donati OF; Ferraro DA; Messerli M; Kranzbühler B; Ter Voert EEGW; Muehlematter UJ; Rupp NJ; Mortezavi A; Eberli D
J Nucl Med; 2019 Aug; 60(8):1118-1123. PubMed ID: 30683764
[TBL] [Abstract][Full Text] [Related]
10. False-positive mpMRI and true-negative
Tang Y; Yang J; Zhou C; Li J; Hu S
Transl Androl Urol; 2022 Apr; 11(4):561-566. PubMed ID: 35558264
[TBL] [Abstract][Full Text] [Related]
11. A Pilot Study of
Duan H; Ghanouni P; Daniel B; Rosenberg J; Davidzon GA; Aparici CM; Kunder C; Sonn GA; Iagaru A
J Nucl Med; 2023 Apr; 64(4):592-597. PubMed ID: 36328488
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic performance of
Ferraro DA; Becker AS; Kranzbühler B; Mebert I; Baltensperger A; Zeimpekis KG; Grünig H; Messerli M; Rupp NJ; Rueschoff JH; Mortezavi A; Donati OF; Sapienza MT; Eberli D; Burger IA
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3315-3324. PubMed ID: 33620559
[TBL] [Abstract][Full Text] [Related]
13. Establishment and prospective validation of an SUV
Jiao J; Kang F; Zhang J; Quan Z; Wen W; Zhao X; Ma S; Wu P; Yang F; Guo W; Yang X; Yuan J; Shi Y; Wang J; Qin W
Theranostics; 2021; 11(17):8396-8411. PubMed ID: 34373749
[No Abstract] [Full Text] [Related]
14. Targeted Prostate Biopsy Using
Simopoulos DN; Natarajan S; Jones TA; Fendler WP; Sisk AE; Marks LS
Urol Case Rep; 2017 Sep; 14():11-14. PubMed ID: 28607878
[TBL] [Abstract][Full Text] [Related]
15. Vesico-urethral anastomosis sampling: a forgotten tool for guiding salvage radiation after radical prostatectomy.
Timm B; Farag M; Liodakis P; Angus D; Lim Joon D; Bolton D
BJU Int; 2021 May; 127 Suppl 1():23-29. PubMed ID: 33973332
[TBL] [Abstract][Full Text] [Related]
16. Prospective comparison of whole-body MRI and
Sawicki LM; Kirchner J; Buddensieck C; Antke C; Ullrich T; Schimmöller L; Boos J; Schleich C; Schaarschmidt BM; Buchbender C; Heusch P; Rabenalt R; Albers P; Antoch G; Müller HW; Hautzel H
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1542-1550. PubMed ID: 30879122
[TBL] [Abstract][Full Text] [Related]
17. Contrast enhanced ultrasound (CEUS) with MRI image fusion for monitoring focal therapy of prostate cancer with high intensity focused ultrasound (HIFU)1.
Apfelbeck M; Clevert DA; Ricke J; Stief C; Schlenker B
Clin Hemorheol Microcirc; 2018; 69(1-2):93-100. PubMed ID: 29660918
[TBL] [Abstract][Full Text] [Related]
18. Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross-sectional study of the additive diagnostic value of gallium-68 prostate-specific membrane antigen positron-emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancer.
Amin A; Blazevski A; Thompson J; Scheltema MJ; Hofman MS; Murphy D; Lawrentschuk N; Sathianathen N; Kapoor J; Woo HH; Chalasani V; Rasiah K; van Leeuwen PJ; Tang R; Cusick T; Stricker P; Emmett L
BJU Int; 2020 Apr; 125(4):515-524. PubMed ID: 31957122
[TBL] [Abstract][Full Text] [Related]
19. Comparison of
Ling SW; de Jong AC; Schoots IG; Nasserinejad K; Busstra MB; van der Veldt AAM; Brabander T
Eur Urol Open Sci; 2021 Nov; 33():61-71. PubMed ID: 34632423
[TBL] [Abstract][Full Text] [Related]
20. Incremental value of 68-gallium-prostate-specific membrane antigen positron emission tomography/computed tomography in patients with abnormal prostate-specific antigen and benign transrectal ultrasound biopsy.
Gupta M; Choudhury PS; Rawal S; Gupta G
Urol Ann; 2018; 10(2):150-153. PubMed ID: 29719325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
